Maze Therapeutics, Inc. Common Stock (MAZE)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Maze Therapeutics, Inc. Common Stock (MAZE) is listed on Nasdaq, where it has traded since January 31, 2025.
- Listed On
- Nasdaq
- Listed Since
- January 31, 2025
- Employees
- 141
- Market Cap
- $1.8B
About Maze Therapeutics, Inc. Common Stock
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 155 institutions reported holding MAZE, with 58.5 million shares worth $1.7 billion in aggregate. The largest reported holder was Frazier Life Sciences Management, with 5.0 million shares worth $150.2 million. Of the 5 largest holders listed below, 3 added shares and 2 held their positions unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Frazier Life Sciences Management | 5,032,915 | $150M | Added 10.2% |
| Trv GP IV | 4,473,958 | $134M | Unchanged |
| Arch Venture Management | 4,120,053 | $123M | Unchanged |
| Deep Track Capital | 3,732,569 | $111M | Added 7.33% |
| BlackRock | 3,502,841 | $105M | Added 36.27% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is MAZE?
Maze Therapeutics, Inc. Common Stock (MAZE) is listed on Nasdaq, where it has traded since January 31, 2025.
Who are the largest institutional holders of MAZE?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of MAZE were Frazier Life Sciences Management, Trv GP IV and Arch Venture Management.
How many institutions own MAZE?
155 institutions reported a position in MAZE for the quarter ended June 30, 2026, worth $1.7 billion in total.
Did institutions buy or sell MAZE last quarter?
Of the 5 largest reported holders, 3 added shares and 2 held their positions unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for MAZE.
Every reported institutional holder, plus insider and congressional trades in MAZE, on SentiSense.